DMAA · Drugs Made In America Acquisition Corp.
$10.85
+0.00 (+0.00%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Additionally, the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed Aug 14, 2026
Market Cap
$263.40M
Shares
24.28M
Volume · Oct 9
903
Avg daily vol (3M)
27.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.85
Open$10.85
Day$10.85–10.85
52W close$10.28–10.89
Avg vol 30d31K
Short int93K · 0.4% float · 1.3d
Short vol8%
DataFeb 2025–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$6.09M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
43.2
Trailing earnings · reciprocal yield 2.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$20,280
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-27.6%
Year over year · fewer shares
Price change (1Y)
+5.3%
Trailing year
Short interest
0.4%
Latest settlement · 1.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+1%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
93%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+3%
trailing
YTD return
+5%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-15% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.38% of float · ▲ +16.5% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
44 holders — mid 1-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
2%
annualized · 1-yr
Max drawdown
0%
past year
ATR
0.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
93%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-15% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.38% of float · ▲ +16.5% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
44 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $10
Now $11 · 93%
Range high $11
vs 200-day avg +3%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAA
this stock
Drugs Made In America Acquisition Corp.
|
$263.40M | +4.6% | — | — | 0.4% |
|
VYLR
Vylor Inc.
|
$53.00B | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
XRPN
Armada Acquisition Corp. II
|
$764.48M | +136.3% | — | — | 0.2% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$649.10M | +2.9% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAA | -0.3% | +0.8% | +3.4% | -0.3% | +4.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -1.6% | -1.3% | -5.6% | -1.8% | -8.9% |
Key facts
CIK
2028614
CUSIP
G2847J104